Exon 21 L858r Point Mutations - Cancer Science

Relevant Publications

Silencing of lncRNA LOC105376794 promotes migration, invasion, and Gefitinib resistance of lung adenocarcinoma cells with EGFR 19Del mutation by ATF4/CHOP axis and ERK phosphorylation.

Issue Release: 2024

Real-world outcomes on platinum-containing chemotherapy for -mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors.

Issue Release: 2024

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations.

Issue Release: 2024

Investigation of the Efficacy of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor in Patients With EGFR Exon 21 L858R Point Mutation-Positive Non-small Cell Lung Cancer.

Issue Release: 2024

Distinguishing EGFR mutation molecular subtypes based on MRI radiomics features of lung adenocarcinoma brain metastases.

Issue Release: 2024

Advances in the Diagnosis and Treatment of Advanced Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.

Issue Release: 2023

How to Treat -Mutated Non-Small Cell Lung Cancer.

Issue Release: 2023

Clinical outcome of Brazilian patients with non-small cell lung cancer in early stage harboring rare mutations in epidermal growth factor receptor.

Issue Release: 2023

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report.

Issue Release: 2023

EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.

Issue Release: 2023

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need.

Issue Release: 2023

[Correlation between Immune Microenvironment Features and EGFR Mutation Status  in Lung Adenocarcinoma].

Issue Release: 2023

Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.

Issue Release: 2023

Dual kinase inhibitor for EGFR mutants and ErbB2 limit breast cancer.

Issue Release: 2023

The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics.

Issue Release: 2023

Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review.

Issue Release: 2023

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With Mutations.

Issue Release: 2023

The development of amivantamab for the treatment of non-small cell lung cancer.

Issue Release: 2023

Lung adenocarcinoma: development of nomograms based on PET/CT images for prediction of epidermal growth factor receptor mutation status and subtypes.

Issue Release: 2022

Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio for -Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated with First-Line EGFR-TKIs: A Large Population-Based Study and Literature Review.

Issue Release: 2022

What role do biomarkers play in cancer treatment?

How Do Blister Packs Benefit Cancer Patients?

How to Prepare for Bone Marrow Aspiration?

What are the Benefits of Telemedicine in Cancer Care?

Which Types of Cancer Are Most Commonly Associated with Dysphagia?

How do Keratins Affect Tumor Behavior?

Which Cancers are Associated with MSI-H?

What are the Challenges in Using Natural Compounds for Cancer Treatment?

How is Processed Meat Linked to Cancer?

Why is Tumor Location Important in Cancer?

Exon 21 L858r Point Mutations - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics